ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk

This guideline emphasizes considerations of both safety and quality risk management in establishing levels of mutagenic impurities that are expected to pose negligible carcinogenic risk. It outlines recommendations for assessment and control of mutagenic impurities that reside or are reasonably expected to reside in final drug substance or product, taking into consideration the intended conditions of human use.

Keywords: Impurities, genotoxicity, mutagenic, carcinogenic

Document history

Current effective version

First version

Superseded version 

How useful was this page?

Add your rating
Average
1 rating
1 rating